Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Demographic and clinical characteristics of patients with sarcopenia and frailty syndrome and geriatric controlSarcopenia (N = 12)Frailty syndrome (N = 36)Geriatric control (n = 25)p-valueAge (years, mean ± SD)77.33 ± 13.7580.50 ± 8.7272.56 ± 13.750.004*Gender0.45*** Women n(%)6 (50.00%)25 (69.44%)17 (68.00%) Men n(%)6 (50.00%)11 (30.56%)8 (31.00%)Mean ± SDp-value* ASMM (kg)5.95 ± 0.907.19 ± 0.747.47 ± 0.80 < 0.0001 FI-CGA0.21 ± 0.110.36 ± 0.090.14 ± 0.060.004 BMI (kg/m^2)23.18 ± 2.9727.61 ± 6.3729.86 ± 5.280.005 Cholesterol (mg/dl)194.50 ± 42.75173.85 ± 41.31204.24 ± 42.990.022 Triglycerides (nmol/l)105.58 ± 42.91138.74 ± 66.59147.04 ± 60.180.154 LDL (mg/dL)100.65 ± 37.6491.06 ± 30.08120.50 ± 37.650.006 Albumin (g/dl)4.17 ± 0,383.98 ± 0.494.10 ± 0.320.289 Hemoglobin (g/dl)12.50 ± 1.6012.11 ± 1.7313.29 ± 1.430.023 LDH (U/L)260.52 ± 61.35252.89 ± 103.61229.81 ± 41.670.443 Creatine (µmol/l)0.97 ± 0.290.88 ± 0.240.89 ± 0.270.605 Vitamin D3 (ng/ml)33.75 ± 34.4336.81 ± 29.6335.09 ± 34.880.850 Vitamin B12 (pg/ml)455.65 ± 245.43397.72 ± 187.11426.20 ± 243.400.704 Serum Fe level (mcg/dl)79.96 ± 10.5061.16 ± 22.8484.11 ± 22.97 < 0.0001Median (IQR)P-value** TUG (s)14.50 (11.70, 21.97)200.00 (14.75, 26.50)14.00 (13.00, 15.00) < 0.0001 ESR (mm/h)11.00 (8.00, 15.50)22.00 (12.50, 35.25)10.00 (8.00, 22.00)0.048 CRP (mg/dl)5.00 (5.00, 6.00)7.00 (5.00, 25.50)5.00 (5.00, 12.00)0.062 NT-proBNP (pg/ml)354.80 (277.88, 666,57)264.30 (163.67, 510.20)258.60 (164.60, 559.60)0.308 CK (U/I)67.00 (55.00, 70.79)71.00 (45.25, 86.50)72.00 (56.00, 106.00)0.382N (%)p-value*** Osteopenia0.009 Present6 (50.00%)4 (11.11%)2 (8.00%) Not present6 (50.00%)32 (88.89)23 (93.00%) NYHA class0.153 07 (58.33%)27 (75.00%)23 (92.00%) I0 (0.00%)1 (2.78%)0 (0.00%) II3 (25.00%)6 (16.67%)1 (4.00%) II-III2 (16.67%)1 (2.78%)1 (4.00%) III0 (0.00%)1 (2.78%)0 (0.00%) Polyarthritis Present4 (33.33%)18 (50.00%)13 (52.00%)0.574 Not present8 (66.67%)18 (50.00%)12 (48.00%) Osteoporosis Present3 (25.00%)9 (25.50%)4 (16.00%)0.691 Not present9 (75.00%)27 (75.00%)21 (84.00%)Abbreviations ADL Activities of daily living, ASMM Appendicular skeletal muscle mass, BMI Body mass index, CRP C-reactive protein, DEXA Dual-energy X-ray absorptiometry, FI-CGA Frailty index-comprehensive geriatric assessment, LDL Low-density lipoprotein, POMA Performance-oriented mobility assessment, TUG Timed up & go, VES Vulnerable elders survey, *in comparison to the group 50 + *One-way analysis of means (not assuming equal variances) or analysis of variance**Kruskal: Wallis rank sum test***Person’s Chi-squared test or Fisher’s Exact Test for Count Data

Source: Patients. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Aging and the impact of global DNA methylation, telomere shortening, and total oxidative status on sarcopenia and frailty syndrome

Study design awaiting verification · Immunity & Ageing : I & A · 2023

Original publication title

Aging and the impact of global DNA methylation, telomere shortening, and total oxidative status on sarcopenia and frailty syndrome

Tomasz Kmiołek; Gabriela Filipowicz; Diana Bogucka; Anna Wajda; Adam Ejma-Multański; Barbara Stypińska; Ewa Modzelewska; Yana Kaliberda; Marcin Radkowski; Tomasz Targowski; Julia Wrona; Agnieszka Paradowska-Gorycka

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Aging is a biological event that influences many organs and systems. Both sarcopenia and frailty syndrome refer to geriatric conditions with overlapping phenotypes. Many mechanisms are involved in the aging process such as DNA methylation telomeres which are susceptible to oxidative stress, and inflammations which result in telomere shortening, leading to chromosomal instability. The study aimed to determine the associations between these processes, frailty and sarcopenia syndrome. Global DNA methylation was analyzed using the ELISA method. Telomere length was analyzed using qPCR.

Total oxidative status (TOS) was analyzed using a colorimetric method. The present study revealed that the main factor affecting methylation, telomeres length and level of total oxidant stress was age.

Authors’ abstract

Aging is a biological event that influences many organs and systems. Both sarcopenia and frailty syndrome refer to geriatric conditions with overlapping phenotypes. Many mechanisms are involved in the aging process such as DNA methylation telomeres which are susceptible to oxidative stress, and inflammations which result in telomere shortening, leading to chromosomal instability. The study aimed to determine the associations between these processes, frailty and sarcopenia syndrome. Global DNA methylation was analyzed using the ELISA method. Telomere length was analyzed using qPCR.

Total oxidative status (TOS) was analyzed using a colorimetric method. The present study revealed that the main factor affecting methylation, telomeres length and level of total oxidant stress was age.

Publication and source details

Original title: Aging and the impact of global DNA methylation, telomere shortening, and total oxidative status on sarcopenia and frailty syndrome

Tomasz Kmiołek; Gabriela Filipowicz; Diana Bogucka; Anna Wajda; Adam Ejma-Multański; Barbara Stypińska; Ewa Modzelewska; Yana Kaliberda; Marcin Radkowski; Tomasz Targowski; Julia Wrona; Agnieszka Paradowska-Gorycka

Immunity & Ageing : I & A · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T14:54:59.810725+00:00

DOI: 10.1186/s12979-023-00384-2 · PMC10644469